Crystal's Coder Hub🔴 ICD-10 CM C77.5 — Secondary Malignant Neoplasm of Intrapelvic Lymph Nodes
Billable Code Confirmed
ICD-10-CM C77.5 is a valid, billable 4-character ICD-10-CM diagnosis code for FY2026. The character structure is: C (neoplasm chapter) → 77 (secondary and unspecified malignant neoplasm of lymph nodes) → .5 (intrapelvic site specificity). No additional characters are required or available — C77.5 is the terminal, fully specified code in this branch.
Non-Billable Parent Codes — Never Submit These
- ❌
C77— 3-character header — site of lymph node involvement is unspecified; not billableAlways submit C77.5 (all 4 characters) when intrapelvic lymph node secondary malignancy is documented. If the intrapelvic site is not specified but lymph node metastasis is confirmed, query the provider for nodal location before defaulting to a less specific code.
Clinical Context: Secondary vs. Primary Lymph Node Malignancy
ICD-10-CM C77.5 captures metastatic spread TO the intrapelvic lymph nodes FROM a primary malignancy elsewhere in the body. It is not used for primary lymphoma or lymphocytic leukemia arising in pelvic nodes — those conditions are classified in C81-C96. The distinction is foundational: C77.5 requires a documented primary malignancy (active or historical) whose cells have disseminated to the intrapelvic nodal basin. Always code the originating primary malignancy alongside C77.5 per sequencing guidelines.
Code Classification
ICD-10-CM Diagnosis Code — wRVU, assistant payable, and global period fields are not applicable to diagnosis codes. For associated procedure coding, refer to the CPT Procedural Crosswalk and ICD-10-PCS Crosswalk sections below. This code drives DRG assignment, HCC risk adjustment, and medical necessity for oncologic procedures.
🔍 Code Description
ICD-10-CM C77.5 classifies secondary (metastatic) malignant neoplasm of the intrapelvic lymph nodes — that is, cancer cells that have spread from a primary tumor site to the lymph nodes located within the pelvic cavity, including the common iliac, external iliac, internal iliac (hypogastric), obturator, and presacral nodal chains.1 This code captures regional nodal spread that is a direct consequence of an existing primary malignancy rather than a de novo lymphatic malignancy.
The intrapelvic lymph node chains serve as the primary regional drainage pathways for pelvic organs — prostate, bladder, uterus, cervix, ovary, rectum, and distal colon — making C77.5 one of the most clinically significant secondary malignancy codes in urologic and gynecologic oncology. Nodal involvement at this level classifies most primary malignancies as at least regional stage (AJCC N1 or higher), directly influencing treatment planning, surgical approach, radiation field design, and prognosis.2,3
🌳 Code Tree / Hierarchy
C77 Secondary and unspecified malignant neoplasm of lymph nodes ❌ Non-billable
│
├── C77.0 Secondary malignant neoplasm of lymph nodes of head, face and neck ✅ Billable
├── C77.1 Secondary malignant neoplasm of intrathoracic lymph nodes ✅ Billable
├── C77.2 Secondary malignant neoplasm of intra-abdominal lymph nodes ✅ Billable
├── C77.3 Secondary malignant neoplasm of axilla and upper limb lymph nodes ✅ Billable
├── C77.4 Secondary malignant neoplasm of inguinal and lower limb lymph nodes ✅ Billable
├── C77.5 Secondary malignant neoplasm of intrapelvic lymph nodes ◀ THIS CODE ✅ Billable
├── C77.8 Secondary malignant neoplasm of lymph nodes of multiple regions ✅ Billable
└── C77.9 Secondary malignant neoplasm of lymph node, unspecified ✅ Billable
C77.5 vs. C77.4 vs. C77.2 — Anatomic Precision Drives Code Selection
The .5 subcategory is specific to intrapelvic nodes (iliac chains, obturator, presacral). Do not confuse with C77.4 (inguinal and lower limb nodes — these are external, below the inguinal ligament) or C77.2 (intra-abdominal nodes — para-aortic, mesenteric, retroperitoneal chains above the pelvic brim). When imaging or operative notes identify both intra-abdominal and intrapelvic nodal involvement, report both C77.2 and C77.5. When multiple distinct regional chains are involved and individually identified, code each; if the documentation is non-specific about which chains are involved beyond “multiple regions,” use C77.8.
✅ Includes
The following clinical terms and scenarios map to C77.5 when documented:
- Metastatic cancer to intrapelvic lymph nodes (common iliac, external iliac, internal iliac, obturator, presacral, lateral sacral nodes)
- Pelvic lymph node metastasis from documented primary malignancy (any site)
- Secondary intrapelvic lymphadenopathy due to known carcinoma
- Pathologically confirmed pelvic nodal involvement on lymph node dissection specimen
- Radiographically suspected intrapelvic nodal metastasis confirmed by provider documentation or pathology
- Regional nodal spread at N1 or above for primary pelvic organ malignancies
❌ Excludes
Excludes 1 — Cannot Be Coded Simultaneously with C77.5
| Code | Description | Note |
|---|---|---|
| C81-C86 | Hodgkin and Non-Hodgkin Lymphoma | Primary lymphoma arising in pelvic nodes is classified here — use C77.5 only when a non-lymphomatous primary tumor (e.g., prostate, bladder, ovary) has metastasized to the intrapelvic nodes; if the pelvic nodal mass IS the primary malignancy (lymphoma), C77.5 is incorrect |
| C91-C95 | Leukemia categories | Leukemic infiltration of pelvic lymph nodes is classified under the leukemia categories, not as secondary neoplasm |
Excludes 1 Violation Risk
The most common error is assigning C77.5 to a patient with a primary pelvic lymphoma (e.g., diffuse large B-cell lymphoma presenting with pelvic adenopathy). If no prior non-lymphomatous primary tumor is documented, the pelvic nodal malignancy is primary lymphoma (C83.xx or appropriate lymphoma category), not secondary neoplasm. Confirm the existence of a prior or concurrent non-lymphomatous primary before assigning C77.5.
Excludes 2 — May Be Coded in Addition if Separately Present
| Code | Description | Note |
|---|---|---|
| C77.2 | Secondary malignant neoplasm of intra-abdominal lymph nodes | Code both C77.2 and C77.5 when imaging or pathology confirms involvement of both intra-abdominal (para-aortic, mesenteric) and intrapelvic nodal chains — each represents a distinct anatomic basin |
| C77.4 | Secondary malignant neoplasm of inguinal and lower limb lymph nodes | Code both when inguinal nodal involvement is separately documented alongside intrapelvic disease |
| C77.8 | Secondary malignant neoplasm of lymph nodes of multiple regions | Use C77.8 instead of listing individual sites when documentation identifies widespread multi-region nodal disease without site-specific enumeration; if individual sites are identified, code each specifically |
📋 Clinical Overview
Primary Malignancies Most Commonly Driving C77.5
The intrapelvic lymph nodes are the primary regional nodal drainage basin for most pelvic organs. The following table summarizes the most common primary malignancies that spread to the intrapelvic nodes and drive C77.5 assignment.
| Primary Site | Primary Code | Nodal Chains Typically Involved | Clinical Notes |
|---|---|---|---|
| Prostate | C61 | Obturator, external iliac, internal iliac | Among the highest-volume drivers of C77.5 in urology; pelvic lymph node dissection (PLND) at prostatectomy; N1 disease at pathology confirms C77.5 assignment |
| Bladder | C67.9 / site-specific | External iliac, obturator, internal iliac | Radical cystectomy with bilateral PLND is standard; pathologic N1-N3 staging triggers C77.5 |
| Cervix | C53.9 / site-specific | Parametrial, internal iliac, obturator | Sentinel node biopsy and systematic PLND; C77.5 when nodes positive |
| Ovary | C56.9 / site-specific | Common iliac, internal iliac, external iliac | Often combined with intra-abdominal spread → code C77.5 + C77.2 |
| Endometrium | C54.1 | Pelvic and para-aortic nodes | FIGO Stage IIIC1 = pelvic nodes positive; C77.5 required |
| Rectum / Sigmoid | C20 / C18.7 | Internal iliac, lateral sacral | Lateral pelvic node dissection in select cases; code C77.5 when lateral pelvic nodes confirmed positive |
| Kidney / Renal Pelvis | C64.x | Common iliac, internal iliac (less common) | Retroperitoneal and pelvic nodal spread; confirm intrapelvic vs. intra-abdominal location on imaging/pathology |
CDI Query Trigger — "Pelvic Lymphadenopathy" vs. Confirmed Metastasis
Radiographic “pelvic lymphadenopathy” in a patient with a known primary malignancy is not automatically C77.5. ICD-10-CM requires a confirmed diagnosis — either pathologic (biopsy/dissection) or a provider statement of metastasis/secondary involvement. If the documentation reads “suspicious pelvic adenopathy” or “possible nodal metastasis,” query the provider for a confirmed diagnosis statement before assigning C77.5. If the provider cannot confirm, code the sign/symptom (R59.1 — Generalized enlarged lymph nodes) with the primary malignancy, not C77.5.
Common Manifestations and Associated Conditions
Patients with C77.5 may present with or develop the following documented manifestations — code each when separately documented:
- Lymphedema of the lower extremities (I89.0) — Obstruction of pelvic nodal drainage by bulky nodal disease or post-dissection
- Hydronephrosis (N13.2 or site-specific) — Ureteral obstruction from bulky intrapelvic nodal mass; important CC that elevates DRG tier
- Pelvic pain (R10.2) — Somatic referral from nodal mass effect on adjacent structures; code when separately documented
- Venous obstruction / DVT (I82.4X1 / I82.4X2) — Compression of iliac veins by pelvic nodal burden
- Pathological fracture (M84.5xx-series) — When nodal disease is accompanied by bony pelvic metastasis
Coding Manifestations
Always code the documented manifestations to fully capture patient complexity and CC/MCC tier. Examples:
- I89.0 — Lymphedema, not elsewhere classified (complication of nodal burden or post-dissection)
- N13.2 — Hydronephrosis with renal and ureteral calculus (or N13.30 — unspecified obstruction, if etiology is nodal compression)
- I82.411 — Acute DVT of right femoral vein (compression by intrapelvic nodal mass)
💰 HCC Risk Adjustment (CMS-HCC v28)
| Field | Detail |
|---|---|
| CMS-HCC Model Version | v28 (2024-2025 Implementation) |
| HCC Assignment | ✅ Mapped — HCC 12 |
| HCC Category | HCC 12 — Metastatic Cancer and Acute Leukemia |
| RAF Coefficient | ~2.87-3.21 (varies by age, dual eligibility status, and Medicaid enrollment) |
C77.5 maps directly to HCC 12 (Metastatic Cancer and Acute Leukemia) under CMS-HCC Model v28 — the highest-weighted oncology HCC category and among the top RAF drivers in the entire model.4 This reflects the clinical reality that active metastatic disease carries extraordinary predicted resource utilization across systemic therapy, surgical intervention, imaging, palliative support, and care coordination.
Capture Annually
HCC 12 must be documented and coded in at least one encounter per calendar year to be included in the RAF score for that payment year. In Medicare Advantage patients with established intrapelvic nodal metastasis, confirm that C77.5 (or another HCC 12-mapping secondary malignancy code) appears on at least one claim annually. A patient with known pelvic nodal metastasis seen for an unrelated condition where the oncologic history is documented but not coded represents a missed HCC capture opportunity — and for high-weight categories like HCC 12, this gap has direct financial and care management consequences.
🏥 MS-DRG Assignment
MDC 17 — Myeloproliferative Diseases and Disorders, Poorly Differentiated Neoplasms
| DRG | Title | Est. Relative Weight* |
|---|---|---|
| DRG 820 | Lymphoma and Leukemia with Major OR Procedure with MCC | ~4.20-5.10 |
| DRG 821 | Lymphoma and Leukemia with Major OR Procedure with CC | ~2.80-3.20 |
| DRG 822 | Lymphoma and Leukemia with Major OR Procedure without CC/MCC | ~1.90-2.30 |
| DRG 826 | Other Lymphoma and Non-Acute Leukemia with MCC | ~2.90-3.50 |
| DRG 827 | Other Lymphoma and Non-Acute Leukemia with CC | ~1.80-2.10 |
| DRG 828 | Other Lymphoma and Non-Acute Leukemia without CC/MCC | ~1.20-1.50 |
Approximate. Verify against IPPS FY2026 Final Rule tables (CMS-1807-F).
Sequencing and Complications
Sequencing rule (ICD-10-CM Guideline Section I.C.2.b): When the patient is admitted for treatment of a secondary malignancy (C77.5), the secondary site may be sequenced as principal diagnosis even if the primary malignancy is still active — sequence the site being treated as principal. When the admission is for a complication of the metastatic disease (e.g., obstructive hydronephrosis, bowel obstruction), the complication may be principal with C77.5 as additional diagnosis. The primary malignancy is always coded as an additional diagnosis when it is still active. As a secondary diagnosis, C77.5 frequently functions as a CC, and when combined with other high-impact secondary diagnoses (e.g., hydronephrosis, DVT, malignant pleural effusion), may contribute to an MCC tier grouping — confirm against the current CMS CC/MCC exclusion table, as secondary malignancy CC/MCC status is subject to principal diagnosis exclusions.
🔗 Related ICD-10-CM Codes
C77 Family — Secondary Malignant Neoplasm by Nodal Region
| Code | Description |
|---|---|
| C77.0 | Secondary malignant neoplasm of lymph nodes of head, face and neck |
| C77.1 | Secondary malignant neoplasm of intrathoracic lymph nodes |
| C77.2 | Secondary malignant neoplasm of intra-abdominal lymph nodes |
| C77.3 | Secondary malignant neoplasm of axilla and upper limb lymph nodes |
| C77.4 | Secondary malignant neoplasm of inguinal and lower limb lymph nodes |
| C77.5 | Secondary malignant neoplasm of intrapelvic lymph nodes ← This Code |
| C77.8 | Secondary malignant neoplasm of lymph nodes of multiple regions |
| C77.9 | Secondary malignant neoplasm of lymph node, unspecified |
Common Co-occurring Secondary Sites
| Code | Description |
|---|---|
| C78.6 | Secondary malignant neoplasm of retroperitoneum and peritoneum |
| C78.7 | Secondary malignant neoplasm of liver and intrahepatic bile duct |
| C79.51 | Secondary malignant neoplasm of bone |
| C79.89 | Secondary malignant neoplasm of other specified sites |
| C77.2 | Secondary malignant neoplasm of intra-abdominal lymph nodes (para-aortic chain — commonly co-occurs with intrapelvic nodal spread in advanced pelvic primaries) |
Common Primary Malignancy Codes Paired with C77.5
| Code | Description |
|---|---|
| C61 | Malignant neoplasm of prostate |
| C67.9 | Malignant neoplasm of bladder, part unspecified |
| C56.1 | Malignant neoplasm of right ovary |
| C56.2 | Malignant neoplasm of left ovary |
| C54.1 | Malignant neoplasm of endometrium |
| C53.9 | Malignant neoplasm of cervix uteri, unspecified |
| C20 | Malignant neoplasm of rectum |
🛠️ Commonly Associated CPT Codes (Oncology / Urology / Inpatient Setting)
Inpatient and Outpatient Setting Context
C77.5 drives medical necessity for surgical lymph node dissection, oncologic imaging, radiation therapy planning, and systemic therapy administration. In the profee setting, the supervising/operating physician bills the procedure CPT; in the outpatient hospital or ASC, the facility bills separately. The following CPT codes are most commonly associated with this diagnosis in the urology, gynecologic oncology, and radiation oncology settings.
| CPT Code | Description | Profee Coding Notes |
|---|---|---|
| 38562 | Limited lymphadenectomy for staging (pelvic and para-aortic) | Robotic or open; supports C77.5 diagnosis when nodal dissection is performed for staging or therapeutic intent; confirm laterality documentation |
| 38564 | Limited lymphadenectomy for staging, retroperitoneal (aortic and/or splenic) | Para-aortic dissection — if combined with pelvic dissection, report both 38562 and 38564; distinct anatomic sites |
| 38765 | Inguinofemoral lymphadenectomy, superficial, in continuity with pelvic lymphadenectomy, including external iliac, hypogastric, and obturator nodes (unilateral) | Complete pelvic lymphadenectomy for gynecologic or urologic malignancy; code bilaterally with modifier -50 or two separate lines with -RT/-LT |
| 38770 | Pelvic lymphadenectomy, including external iliac, hypogastric, and obturator nodes (unilateral) | Radical pelvic lymph node dissection; most common in radical cystectomy and radical prostatectomy for node-positive disease |
| 78816 | PET imaging, skull base to mid-thigh | Primary staging/restaging imaging modality for confirming extent of intrapelvic nodal involvement; requires supporting diagnosis documentation |
| 77301 | Intensity modulated radiation therapy (IMRT) planning | When C77.5 drives pelvic nodal radiation treatment planning |
| 96413 | Chemotherapy administration, intravenous, up to 1 hour | Systemic therapy directed at metastatic pelvic nodal burden |
NCCI Bundling Considerations
- 38770 (38770) billed on the same day as radical prostatectomy (55840 or 55866) — pelvic lymphadenectomy is separately reportable when performed as a distinct surgical service at the same session; ensure both are documented in the operative report with separate descriptions; apply modifier -51 to the lower-valued procedure per multiple procedure rules.
- 78816 (78816) billed with interpretation-only services — when the nuclear medicine physician interprets the PET but does not perform technical acquisition, modifier -26 (professional component) is required on the profee claim.
🔬 ICD-10-PCS Crosswalk (Inpatient Procedures)
When C77.5 is an inpatient diagnosis, the following PCS codes are relevant for associated inpatient procedures assigned by the facility coder.
| PCS Section | Body System | Root Operation | Clinical Application |
|---|---|---|---|
| 0 (Medical and Surgical) | 7 (Lymphatic and Hemic Systems) | T (Resection) | Complete pelvic lymph node dissection (bilateral) — 07TCZZ; assigned when all lymphatic tissue within the intrapelvic basin is resected |
| 0 (Medical and Surgical) | 7 (Lymphatic and Hemic Systems) | B (Excision) | Selective/partial pelvic lymphadenectomy or sentinel node excision — 07BCZZZ; used when only a portion of the intrapelvic nodal tissue is removed |
| 0 (Medical and Surgical) | 7 (Lymphatic and Hemic Systems) | C (Extirpation) | Removal of pathologic nodal matter (e.g., debulking of matted pelvic nodes) — 07CCZZ |
| D (Radiation Therapy) | 7 (Lymphatic and Hematologic System) | 0 (Beam Radiation) | External beam radiation to intrapelvic nodal field — D7063ZZ (Lymphatics, Pelvis, Photons >10 MeV, No Qualifier) |
💊 Coding Scenarios and Examples
Scenario 1 — Inpatient: Radical Prostatectomy with Pathologic Pelvic Nodal Metastasis
Clinical Vignette: A 68-year-old male with Gleason 9 (ISUP Grade Group 5) prostate adenocarcinoma is admitted for robot-assisted radical prostatectomy with bilateral pelvic lymph node dissection. Preoperative staging MRI suggested suspicious right obturator and external iliac adenopathy. Final pathology confirms: prostate adenocarcinoma, Gleason 9, positive surgical margins; 3 of 14 pelvic lymph nodes positive for metastatic carcinoma. The urologist documents “pathologic N1 prostate cancer with positive intrapelvic lymph nodes” in the operative and discharge summary.
Principal Diagnosis:
- C61 — Malignant neoplasm of prostate (reason for surgical admission and primary site)
Secondary Diagnoses:
- C77.5 — Secondary malignant neoplasm of intrapelvic lymph nodes (pathologically confirmed N1 nodal metastasis — HCC 12 capture)
MS-DRG Assignment: With C77.5 as a secondary diagnosis alongside C61 and the surgical procedure (55866 — laparoscopic/robotic radical prostatectomy), the case groups based on the OR procedure performed. C77.5 contributes as a CC/MCC secondary diagnosis and elevates DRG weight. Confirm grouping against FY2026 IPPS grouper — the combination of radical prostatectomy with confirmed nodal metastasis typically lands in a higher-weighted surgical DRG tier.
Scenario 2 — Inpatient: Admission for Obstructive Hydronephrosis from Bulky Pelvic Nodal Disease
Clinical Vignette: A 58-year-old female with a history of endometrial adenocarcinoma (treated 2 years prior with hysterectomy and adjuvant chemotherapy) is admitted with right flank pain and rising creatinine. CT abdomen/pelvis reveals bilateral hydronephrosis with right ureteral obstruction at the level of the right external iliac nodal mass, measuring 4.2 cm, consistent with recurrent/metastatic endometrial carcinoma. The oncologist documents “recurrent endometrial carcinoma with intrapelvic lymph node metastasis causing right ureteral obstruction and hydronephrosis.”
Principal Diagnosis:
- N13.1 — Hydronephrosis with ureteral stricture, not elsewhere classified (obstructive hydronephrosis is the condition requiring immediate treatment and driving admission)
Secondary Diagnoses:
- C77.5 — Secondary malignant neoplasm of intrapelvic lymph nodes (cause of ureteral obstruction; metastatic endometrial carcinoma; HCC 12)
- C54.1 — Malignant neoplasm of endometrium (primary site — still coded as active per guidelines when there is recurrent/metastatic disease)
- N18.30 — Chronic kidney disease, stage 3 (if documented — obstruction-related renal insufficiency; potential CC)
MS-DRG Assignment: The hydronephrosis with ureteral obstruction as principal (N13.1) groups to MDC 11 (Kidney and Urinary Tract). C77.5 as a secondary diagnosis functions as a CC, elevating the DRG tier within the kidney/urinary tract surgical or medical family depending on whether a ureteral stent or nephrostomy tube procedure is performed during the admission.
Scenario 3 — CDI Query: “Pelvic Lymphadenopathy” in a Patient with Known Prostate Cancer
Clinical Vignette: A 72-year-old male with a history of prostate cancer (C61, diagnosed 3 years ago, on androgen deprivation therapy) is admitted for a rising PSA and new-onset bilateral leg edema. Pelvic MRI reads: “Multiple enlarged pelvic lymph nodes, largest measuring 2.8 cm in the right obturator chain, highly suspicious for metastatic involvement.” The attending’s H&P documents “pelvic lymphadenopathy — likely metastatic prostate cancer” but does not use the word “confirmed” or “metastatic.” The discharge summary lists “pelvic lymphadenopathy” without further qualification.
Action / Outcome: The documentation “likely metastatic prostate cancer” is an uncertain diagnosis in the outpatient/profee context but may be codeable in the inpatient setting under ICD-10-CM Guideline Section II.B, which permits coding conditions documented as “likely” on the inpatient discharge summary. However, to maximize code specificity and ensure the record supports HCC 12 capture, a CDI query is best practice to secure an unambiguous confirmation statement.
Query Response: Provider updates the discharge summary to confirm: “Pelvic lymphadenopathy consistent with and documented as metastatic prostate carcinoma to the intrapelvic lymph nodes, pathologic correlation pending outpatient biopsy; clinical diagnosis confirmed at this time.”
Corrected ICD-10-CM Coding:
- C77.5 — Secondary malignant neoplasm of intrapelvic lymph nodes (confirmed metastatic prostate carcinoma to intrapelvic nodes — HCC 12)
- C61 — Malignant neoplasm of prostate (active primary — always coded as additional when secondary site is present)
⚠️ Coding Pitfalls and Tips
| Pitfall or Tip | |
|---|---|
| ❌ | Coding C77.5 without a documented primary malignancy. C77.5 is a secondary neoplasm code — it requires a known or concurrent primary. If the primary is unknown, assign C80.1 (Malignant neoplasm, unspecified — unknown primary) alongside C77.5. Never leave C77.5 as a standalone diagnosis without a primary malignancy code. |
| ❌ | Using C77.9 (unspecified lymph node) when intrapelvic is documented. When imaging, pathology, or the provider’s documentation specifies pelvic or intrapelvic nodal involvement, C77.5 is required. Defaulting to C77.9 abandons specificity, understates disease burden, and misses the HCC 12 capture opportunity — HCC 12 maps from any C77.x code, but specificity is a compliance requirement regardless. |
| ❌ | Confusing C77.5 (intrapelvic) with C77.4 (inguinal). Intrapelvic nodes (iliac chains, obturator, presacral) are inside the pelvic cavity. Inguinal nodes are external, below the inguinal ligament. Operative notes and imaging reports will specify — read carefully before code selection. When both basins are involved, report both C77.5 and C77.4. |
| ✅ | Always code the active primary malignancy alongside C77.5. Per ICD-10-CM Section I.C.2, when both primary and secondary malignancies are documented and clinically active, code both — the secondary site does not replace the primary. The primary drives DRG logic and HCC category in most cases; omitting it is a compliance deficiency and a CDI gap. |
| ✅ | Capture C77.5 annually for every Medicare Advantage patient with active intrapelvic nodal metastasis. HCC 12 (Metastatic Cancer and Acute Leukemia) is among the highest-weighted HCC categories in CMS-HCC v28. If C77.5 (or any other HCC 12-mapping code) is not documented and coded at least once per calendar year, the RAF score for that beneficiary resets — regardless of how well the prior year’s record was coded. Build an annual capture workflow for all active metastatic diagnoses. |
| ✅ | Code all documented manifestations — lymphedema, hydronephrosis, DVT — as additional diagnoses. These are not bundled into C77.5. Each separately documented complication or associated condition is independently codeable, and many (hydronephrosis, DVT) carry CC/MCC weight that elevates DRG tier and captures full clinical complexity for risk adjustment and quality reporting. |
📚 Sources
1 CMS/NCHS. ICD-10-CM Official Guidelines for Coding and Reporting, FY2026. Section I.C.2 — Neoplasms. · 2 American Joint Committee on Cancer (AJCC). AJCC Cancer Staging Manual, 9th Edition. Pelvic Lymph Node Classification — TNM N Staging for Prostate, Bladder, Cervix, Endometrium, and Colorectal. · 3 National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology — Prostate Cancer, Bladder Cancer, Endometrial Carcinoma, Cervical Cancer. (Current edition.) · 4 CMS. 2024-2025 Medicare Advantage Risk Adjustment — CMS-HCC Model v28 ICD-10-CM Mappings. HCC 12 — Metastatic Cancer and Acute Leukemia. · 5 CMS. IPPS Final Rule FY2026 — MS-DRG Definitions Manual v43. MDC 17 Logic Tables — Myeloproliferative Diseases and Poorly Differentiated Neoplasms. · 6 CMS. MS-DRG Grouper FY2026 — CC/MCC Exclusion Tables. · 7 AMA. CPT Professional Edition 2025. Surgery — Lymph Nodes and Lymphatic Channels (38562, 38564, 38765, 38770). · 8 AAPC. ICD-10-CM Expert for Physicians, FY2026. Tabular List — C77 Secondary Malignant Neoplasm of Lymph Nodes. · 9 Abdollah F, et al. (2012). Extended pelvic lymphadenectomy in prostate cancer — a meta-analysis. European Urology, 61(6), 1176-1185. (Nodal basin anatomy and clinical staging context.) · 10 Cibula D, et al. (2018). The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients with Cervical Cancer. International Journal of Gynecological Cancer, 28(4), 641-655.